- Home
- SGU vs ALXO Comparison
SGU vs ALXO Comparison
Compare SGU & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- ALXO
- Stock Information
- Founded
- SGU 1995
- ALXO 2015
- Country
- SGU United States
- ALXO United States
- Employees
- SGU N/A
- ALXO N/A
- Industry
- SGU Other Specialty Stores
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- SGU Consumer Discretionary
- ALXO Health Care
- Exchange
- SGU Nasdaq
- ALXO Nasdaq
- Market Cap
- SGU 391.0M
- ALXO 81.1M
- IPO Year
- SGU 1995
- ALXO 2020
- Fundamental
- Price
- SGU $11.94
- ALXO $1.51
- Analyst Decision
- SGU
- ALXO Strong Buy
- Analyst Count
- SGU 0
- ALXO 6
- Target Price
- SGU N/A
- ALXO $14.20
- AVG Volume (30 Days)
- SGU 18.2K
- ALXO 518.7K
- Earning Date
- SGU 12-04-2024
- ALXO 11-11-2024
- Dividend Yield
- SGU 5.76%
- ALXO N/A
- EPS Growth
- SGU 818.35
- ALXO N/A
- EPS
- SGU 1.24
- ALXO N/A
- Revenue
- SGU $1,792,705,000.00
- ALXO N/A
- Revenue This Year
- SGU N/A
- ALXO N/A
- Revenue Next Year
- SGU N/A
- ALXO N/A
- P/E Ratio
- SGU $9.62
- ALXO N/A
- Revenue Growth
- SGU N/A
- ALXO N/A
- 52 Week Low
- SGU $9.64
- ALXO $1.42
- 52 Week High
- SGU $14.76
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- SGU 58.12
- ALXO 30.69
- Support Level
- SGU $11.14
- ALXO $1.42
- Resistance Level
- SGU $12.01
- ALXO $1.62
- Average True Range (ATR)
- SGU 0.41
- ALXO 0.12
- MACD
- SGU 0.04
- ALXO 0.03
- Stochastic Oscillator
- SGU 61.07
- ALXO 15.79
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. It offers heating and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.